TP53 and cancer: The interest in PARP inhibitors in the context of endometrial cancer stems from the fact that HRD is associated with the P53 mutation, which occurs in serous endometrial cancer, and in addition, HRD tumors are characterized by an increased immune response directed against cancer cells.